Jacobio Pharmaceuticals Group First Half 2024 Earnings: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023)
Jacobio Pharmaceuticals Group (HKG:1167) First Half 2024 Results
Key Financial Results
- Net loss: CN¥169.1m (loss widened by 1.7% from 1H 2023).
- CN¥0.22 loss per share (further deteriorated from CN¥0.22 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Jacobio Pharmaceuticals Group Earnings Insights
Looking ahead, revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Hong Kong are expected to grow by 28%.
Performance of the Hong Kong Biotechs industry.
The company's shares are up 9.2% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Jacobio Pharmaceuticals Group that you should be aware of before investing here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:1167
Jacobio Pharmaceuticals Group
An investment holding company, engages in the in-house discovery and development of oncology therapies.
Flawless balance sheet and slightly overvalued.
